Meridian Bioscience (NASDAQ:VIVO) issued its quarterly earnings data on Thursday. The company reported $0.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.04, Briefing.com reports. Meridian Bioscience had a net margin of 12.65% and a return on equity of 17.82%. The business had revenue of $50.80 million during the quarter, compared to analyst estimates of $50.57 million. During the same period in the prior year, the business earned $0.20 EPS. The company’s revenue for the quarter was down 4.3% on a year-over-year basis. Meridian Bioscience updated its FY20 guidance to $0.28-0.34 EPS.
Shares of Meridian Bioscience stock opened at $7.90 on Friday. The company has a 50-day moving average of $9.64 and a 200 day moving average of $10.75. The company has a debt-to-equity ratio of 0.40, a current ratio of 6.93 and a quick ratio of 4.75. The firm has a market cap of $431.39 million, a price-to-earnings ratio of 10.68 and a beta of 0.37. Meridian Bioscience has a 1 year low of $7.62 and a 1 year high of $19.84.
Several research analysts have commented on the stock. Zacks Investment Research lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. BidaskClub upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. ValuEngine upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Canaccord Genuity reiterated a “sell” rating and issued a $9.00 price target on shares of Meridian Bioscience in a research note on Wednesday, July 31st. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $11.25.
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Further Reading: How is the LIBOR rate calculated?
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.